Expertise in
3
conditions

Suxia X. Luo

127 Dongming Road, 
Zhengzhou, CN 
Expertise in
3
conditions
127 Dongming Road, 
Zhengzhou, CN 
OverviewLocationsClinical Research

Overview

Suxia Luo practices in Zhengzhou, China. Luo is highly rated in 3 conditions, according to our data. Their top areas of expertise are Esophageal Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Gastrectomy, and Hysterectomy.

Their clinical research consists of co-authoring 135 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

127 Dongming Road, Zhengzhou, 450000, China
Other Locations
No. 180 Fenglin Road, Shanghai, 200032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: SI-B003
Study Phase: Phase 1
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: CMG901
Study Phase: Phase 1
Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drugs: SHR-1210, Trastuzumab, Oxaliplatin, Capecitabine
Study Phase: Phase 2
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Enrollment Status: Unknown
Publish Date: April 27, 2020
View 3 Less Clinical Trials

135 Total Publications

Function evaluation of urinary, bowel, pelvic floor functions of patients after nerve-sparing radical hysterectomy based on CC-PRO137 scale
Function evaluation of urinary, bowel, pelvic floor functions of patients after nerve-sparing radical hysterectomy based on CC-PRO137 scale
Journal: Zhonghua yi xue za zhi
Published: September 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Luo's expertise for a condition
ConditionClose
      View All 30 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile